ME 102Alternative Names: AutoVac™ prostrate cancer vaccine; AutoVac™ PSMA pharmaccine; AutoVac™ PSMA vaccine - Pharmexa; Prostate cancer vaccine - Pharmexa
Latest Information Update: 10 Jul 2007
At a glance
- Originator Pharmexa
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 22 Jun 2001 M&E Biotech is now called Pharmexa
- 27 Nov 1998 Preclinical development for Prostate cancer in Denmark (Unknown route)